Search
Close this search box.

Programs

Our programs are focused on expanding the radiopharmaceutical
field through our own discovery programs and in collaboration
with our partners. CPDC’s expertise lies in both the pre-clinical
development of new diagnostic probes and advancing important
radiopharmaceuticals to the clinic and market.

Our programs are focused on expanding the radiopharmaceutical
field through our own discovery programs and in collaboration
with our partners. CPDC’s expertise lies in both the pre-clinical
development of new diagnostic probes and advancing important
radiopharmaceuticals to the clinic and market.

PSMA - 1007

Prostate cancer is the third leading cause
of death from cancer among Canadian
men. To increase the number of prostate
cancer-specific diagnostic agents in
Canada, CPDC is sponsoring a Phase III
clinical trial of [18F]PSMA-1007. The
agent targets prostate specific
membrane antigen (PSMA) protein which
is overexpressed in prostate cancer.

Prostate cancer is the third leading cause
of death from cancer among Canadian
men. To increase the number of prostate
cancer-specific diagnostic agents in
Canada, CPDC is sponsoring a Phase III
clinical trial of [18F]PSMA-1007. The
agent targets the prostate specific
membrane antigen (PSMA) protein which
is overexpressed in prostate cancer.

CPDC holds exclusive licensing rights for PSMA-1007 from ABX GmbH (Radeberg, Germany) to manufacture, commercialize and distribute the imaging agent in Canada. Through a sublicensing manufacturing agreement with Lawson Health Research Institute (London, Canada), CPDC is focused on bringing a critically important diagnostic tool for prostate cancer to the Canadian market.

CPDC’s Phase 3 clinical trial (CPD-002) is a prospective, single arm, non-randomized, open label study of 100 men with suspected persistent or recurrent prostate cancer based on detectable levels of prostate serum antigen (PSA). Patient enrollment began in 2021 and the trial is expected to conclude Q1 2023.

For additional information about the clinical trial, visit www.clinicaltrials.gov (NCT04644822).

CPDC holds exclusive licensing rights for PSMA-1007 from ABX GmbH (Radeberg, Germany)
to manufacture, commercialize and distribute the imaging agent in Canada. Through a
sublicensing manufacturing agreement with Lawson Health Research Institute (London,
Canada), CPDC is focused on bringing a critically important diagnostic tool for prostate
cancer to the Canadian market.

CPDC’s Phase 3 clinical trial (CPD-002) is a prospective, single arm, non-randomized, open
label study of 100 men with suspected persistent or recurrent prostate cancer based on
detectable levels of prostate serum antigen (PSA). Patient enrollment began in 2021 and the
trial is expected to conclude Q1 2023.

For additional information about the clinical trial, visit www.clinicaltrials.gov (NCT04644822).